Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (76,009)	$ (61,381)	$ (31,085)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,819	3,596	3,120
Impairment of assets	824		1,592
Reduction in carrying amount of right-of-use asset	7,236	1,056	1,045
Stock based compensation	19,172	7,395	1,006
Non-cash interest expense		111	320
Loss on debt extinguishment		272
Revaluation of contingent consideration	817
Loss (income) from unconsolidated joint venture	130	(41)
Donation of common stock	2,272	2,226
Losses on marketable securities	1,855	2,002
Loss on sale of property and equipment	47	20
Inventory write-off	133		(15)
Amortization of deferred costs on convertible notes	1,718
Deferred taxes benefit	(653)	(179)
Restructuring charge	1,549
Changes in other assets and liabilities:
Accounts receivable, net	(16,923)	(11,117)	(2,130)
Inventory	351	293	(956)
Prepaid expenses	(1,616)	(4,025)	(210)
Other assets	(7,016)	464	(469)
Accounts payable	(215)	5,215	(2,350)
Accrued expenses	403	(12,008)	8,569
Contract liabilities	515	(1,625)	518
Lease liabilities	(5,727)	(845)	(1,004)
Income taxes payable	743
Net cash used in operating activities	(62,575)	(68,571)	(22,049)
Cash flows from investing activities:
Purchase of marketable securities	(284,096)	(267,467)
Proceeds from sale of marketable securities	58,927	235,000
Purchase of short-term investments			(17,711)
Proceeds from short-term investments			28,571
Purchases of property and equipment	(13,650)	(6,262)	(4,190)
Proceeds from life insurance		627
Proceeds from sale of property and equipment	189
Cash paid for business combinations, net of cash acquired		(174,646)
Net cash provided by (used in) investing activities	(238,630)	(212,748)	6,670
Cash flows from financing activities:
Proceeds from issuance of Series A-2, Series B, Series C, Series D and Series E convertible preferred stock, net of issuance costs			52,409
Repurchase of Series A-2, Series B, Series C and Series D convertible preferred stock			(12,852)
Deemed dividend to preferred stockholders			(8,801)
Proceeds from initial public offering, net of underwriters' discount		325,263
Payments in connection with initial public offering		(3,678)
Proceeds from stock options exercised	3,715	2,291	518
Proceeds from term loan			4,000
Repayment of term loan		(16,136)
Proceeds from the exercise of warrants		40
Proceeds from issuance of convertible notes	287,500
Costs incurred in connection with issuance of convertible notes	(9,309)
Payment of contingent consideration	(932)
Proceeds from other borrowings			4,783
Repayment of other borrowings			(4,783)
Payments on finance lease obligations	(2)	(12)	(13)
Net cash provided by financing activities	280,972	307,768	35,261
Effect of foreign currency translation on cash and cash equivalents	(367)	(61)	(130)
Net (decrease) increase in cash and cash equivalents	(20,600)	26,388	19,752
Cash and cash equivalents at beginning of the year	86,262	59,874	40,122
Cash and cash equivalents at end of the year	65,662	86,262	59,874
Supplemental cash flow information:
Cash paid for interest	1,414	907	$ 1,269
Non-cash investing and financing activities:
Non-cash purchase of property and equipment	279
Non-cash consideration in connection with business combinations	$ (518)	2,339
Shares issued in business combinations		$ 102,888